Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 20701432)

1.

The 6-month persistence on SSRIs and associated economic burden.

Ereshefsky L, Saragoussi D, Despiégel N, Hansen K, François C, Maman K.

J Med Econ. 2010;13(3):527-36. doi: 10.3111/13696998.2010.511050.

PMID:
20701432
2.

Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs.

Yu AP, Ben-Hamadi R, Wu EQ, Kaltenboeck A, Bergman R, Xie J, Blum S, Erder MH.

J Med Econ. 2011;14(4):508-15. doi: 10.3111/13696998.2011.593602. Epub 2011 Jun 21.

PMID:
21692605
3.

Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons.

Wu EQ, Ben-Hamadi R, Yu AP, Tang J, Haim Erder M, Bose A.

J Med Econ. 2010;13(2):314-23. doi: 10.3111/13696998.2010.488985.

PMID:
20504111
4.

The SSRI therapeutic effective dose model.

Derkacz M, Regan T.

Manag Care. 2002 Aug;11(8 Suppl):16-20; discussion 21-5. No abstract available.

5.

Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.

Hylan TR, Crown WH, Meneades L, Heiligenstein JH, Melfi CA, Croghan TW, Buesching DP.

J Affect Disord. 1998 Jan;47(1-3):71-9.

PMID:
9476746
6.
7.

Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: the APEX Study.

Monfared AA, Han D, Sheehy O, Bexton B, Lelorier J.

Curr Med Res Opin. 2006 Jan;22(1):83-94.

PMID:
16393434
8.

One-year costs of second-line therapies for depression.

Sullivan EM, Griffiths RI, Frank RG, Strauss MJ, Herbert RJ, Clouse J, Goldman HH.

J Clin Psychiatry. 2000 Apr;61(4):290-8.

PMID:
10830151
9.

Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs.

Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH.

J Med Econ. 2009 Jun;12(2):124-35. doi: 10.3111/13696990903093537.

PMID:
19566483
10.

Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.

Sheehan DV, Eaddy MT, Shah MB, Mauch RP.

Am J Manag Care. 2005 Oct;11(12 Suppl):S354-61.

11.

Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety.

Wan GJ, Crown WH, Berndt ER, Finkelstein SN, Ling D.

Manag Care Interface. 2002 Jun;15(6):24-30.

PMID:
12087603
12.

Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes.

Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC.

Med Care. 2006 Apr;44(4):300-3.

PMID:
16565629
13.

Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.

Russell JM, Berndt ER, Miceli R, Colucci S, Grudzinski AN.

Am J Manag Care. 1999 May;5(5):597-606.

15.
16.

Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.

Tournier M, Moride Y, Crott R, du Fort GG, Ducruet T.

J Affect Disord. 2009 May;115(1-2):160-6. doi: 10.1016/j.jad.2008.07.004. Epub 2008 Aug 9.

PMID:
18694602
17.

A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.

Peveler R, Kendrick T, Buxton M, Longworth L, Baldwin D, Moore M, Chatwin J, Goddard J, Thornett A, Smith H, Campbell M, Thompson C.

Health Technol Assess. 2005 May;9(16):1-134, iii.

18.
19.

Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.

Einarson TR, Addis A, Iskedjian M.

Pharmacoeconomics. 1997 Aug;12(2 Pt 2):286-96.

PMID:
10170453
20.

Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.

Griffiths RI, Sullivan EM, Frank RG, Strauss MJ, Herbert RJ, Clouse J, Goldman HH.

Pharmacoeconomics. 1999 May;15(5):495-505.

PMID:
10537966
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk